GSK ’s Candidate Shingles Vaccine Shows High Efficacy Against Shingles and its Complications in Adults Aged 70 Years and Over

14 September 2016 -- GSK (LSE/NYSE: GSK) today announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix, showing 90% efficacy in adults aged 70 years and older that is...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials